Occuity

30/09/2026

Occuity has been named Great British Innovator of the Year!

Selected from 30 strong contenders at the Great British Business & Community Awards 2026, this national award recognises our work developing handheld, non-contact optical devices to make healthcare screening and monitoring easier, safer and more accessible.

It’s a proud moment for the whole team, and a chance to thank our partners, clinical collaborators, distributors, investors and everyone who has supported us along the way.

From the PM1 Pachymeter to the AX1 Axiometer and our wider technology pipeline, we’re proud to fly the flag for British innovation.

Read the full story: https://zurl.co/Zi907

28/09/2026

Occuity will be at AAO 2026 in New Orleans from 10–12 October, exhibiting with its South American distributor, ALT Medical Device Inc., on Stand 4403.

Richard Kadri-Langford will be demonstrating the latest AX1 Axiometer and giving visitors the opportunity to experience just how quick, easy and intuitive it is to use.

With significant interest in the AX1 from across the US and around the world, AAO provides an excellent opportunity to get hands-on with the device.

Find out more: https://zurl.co/iB5o1

Occuity will be attending AAO 2026 in New Orleans - Showcasing teh AX1 for Myopia Management

06/09/2026

Discover the AX1 at ESCRS - Axial length measurement is becoming an increasingly important part of effective myopia management, but existing equipment can make it difficult to incorporate into every practice and every consultation.

The Occuity AX1 Axiometer™ is being developed to change that.

If you are a leader in myopia management, a clinician, researcher or KOL attending ESCRS 2026, we would value the opportunity to show you the AX1 and hear your perspective.

Meetings are available close to ExCeL London from 10–14 September.

Find out more and book a time:
https://zurl.co/3DDRO

01/09/2026

Occuity is continuing to build its international distribution network for the PM1 Pachymeter and planned launch of the AX1 Axiometer™.

We already work with ophthalmic partners in a growing number of markets, but there are still regions where we do not yet have distribution coverage.

If your organisation distributes ophthalmic technology and is interested in a compact, handheld, non-contact axial length device designed around the needs of clinicians and children, we would be delighted to meet you during ESCRS 2026.

Meetings are available close to ExCeL London from 10–14 September.

Book a meeting with the Occuity team:
https://zurl.co/7Ggcd

31/08/2026

Are you attending ESCRS 2026 in London?

The Occuity team will be hosting meetings close to ExCeL London from 10–14 September, giving ophthalmic professionals the opportunity to meet the team and see the exciting AX1 Axiometer™.

The AX1 is being developed to make axial length measurement quick, simple and accessible through a compact, handheld, non-contact device.

We’re particularly interested in meeting:

• Myopia management leaders and clinicians
• Key opinion leaders and researchers
• Potential distributors and commercial partners
• Organisations interested in introducing the AX1 to new markets

Find out more and book a meeting:
https://zurl.co/iMVB2

Occuity will be in London for the 44th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), taking place at ExCeL London from 11 to 15 September 2026.We are inviting our existing distributors, potential partners and anyone interested in discovering more about Occuity’s inn...

28/08/2026

Axial length measurement is becoming an increasingly important part of effective myopia management, but existing equipment can make it difficult to incorporate into every practice and every consultation.

The Occuity AX1 Axiometer™ is being developed to change that.

If you are a leader in myopia management, a clinician, researcher or KOL attending ESCRS 2026, we would value the opportunity to show you the AX1 and hear your perspective.

Meetings are available close to ExCeL London from 10–14 September.

Find out more and book a time:
https://zurl.co/CEu8A

21/08/2026

We’re growing the Occuity team.

Occuity develops innovative, non-contact optical devices for healthcare screening and monitoring, and we’re currently recruiting for three full-time positions at our headquarters in Reading:

• Fibre Splicer Technician – Medical Devices
• R&D Technician – Medical Devices
• Design Engineer – Medical Devices

These are hands-on roles offering the opportunity to work within a multidisciplinary team and contribute directly to the development of our next generation of medical devices.

Find out more and apply:
https://zurl.co/cqsuN

16/07/2026

We are delighted to announce that Occuity has secured a major £1.5 million Innovate UK grant to advance our SD1 diabetes and pre-diabetes risk-assessment technology.

Occuity was selected as one of just eight projects funded from 347 applications to the Biomedical Catalyst 2025 programme. That represents a success rate of approximately 2.3%.

This is an exceptional achievement for our team and a significant external endorsement of Occuity’s technology, expertise and long-term vision.

The funding will support the continued development and clinical validation of SD1, a handheld, non-contact optical device designed to help identify people who may benefit from further investigation and referral into existing clinical pathways.

Read the full announcement:

https://zurl.co/TXg4a

Occuity has secured a major £1.5 million Innovate UK grant after being selected as one of just eight projects funded from 347 applications to the Biomedical Catalyst 2025 programme.

11/06/2026

Occuity have been named a finalist in the Hard Tech Investment of the Year category at the UKBAA Angel Investment Awards 2026, recognising innovation in healthcare technology and the support of early-stage investors.

Read more here: https://zurl.co/r2uL4

We are delighted to announce that Occuity has been named a finalist in the Hard Tech Investment of the Year category at the UK Business Angels Association (UKBAA) Angel Investment Awards 2026.The award recognises outstanding companies and investors operating in research-intensive and capital-intensi...